Roy Xie
Managing Director and Head of Healthcare Investments @ Loyal Valley Capital
Shanghai, China
Roy Xie is a Series B investor at Loyal Valley Capital in Shanghai focused on Biotechnology and Life Science. Roy Xie is the Managing Director and head of healthcare Investments of Loyal Valley Capital. Roy attended Southeast University.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 80%
Last updated:
For AI agents: llms.txt
Industries Roy Xie invests in
Stages Roy Xie invests in
Countries Roy Xie invests in
Investment Focus
Industry
- Biotechnology 3 (60%)
- Life Science 2 (40%)
- Therapeutics 2 (40%)
- Medical 1 (20%)
- Genetics 1 (20%)
Stage
- Series B 3 (60%)
- Series A 1 (20%)
- Series C 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Medilink Therapeutics
|
MediLink Therapeutics has established its R&D center in Suzhou, China. The company focuses on developing next generation drug conjugates, and aims to serve the vast unmet medical needs in China, and create global value through conducting multicenter clinical trials and cross-border collaborations. | $70M / Series B / Mar 14, 2022 | |
Alebund Pharmaceuticals
|
Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions. | $54.5M / Series B / Sep 13, 2021 | |
Arctic Vision
|
Arctic Vision is a China-based clinical-stage specialty ophthalmology company with a leading portfolio of breakthrough technologies. The Company's vision is to address ophthalmology's unmet needs through innovative therapies in China, Asia, and globally. Arctic Vision is established by top-tier life sciences investors and led by an eliteteam of ophthalmic industry veterans with substantial and compelling China and global experiences in R&D and commercialization of eye care products. | $100M / Series B / Mar 09, 2021 | |
|
Medilink Therapeutics
|
MediLink Therapeutics has established its R&D center in Suzhou, China. The company focuses on developing next generation drug conjugates, and aims to serve the vast unmet medical needs in China, and create global value through conducting multicenter clinical trials and cross-border collaborations. | $50M / Series A / Mar 01, 2021 | |
CARsgen Therapeutics
|
CARsgen is a leading clinical-stage immunotherapy company focused on the development of new chimeric antigen receptor T (CAR-T) cell therapeutics for liver, lung, stomach and brain cancers. The company has partnership with Shanghai Cancer Institute and Shanghai Renji Hospital. The company is leading the first tier of CAR-T development, bycompleting World’s first hepatocellular carcinoma (HCC) and China’s exclusive glioblastoma multiforme (GBM) dose ascending injection tests. Funded by leading venture capital firm BVCF, CARsgen is well-positioned to bring a novel cancer therapeutics to the market in China and worldwide. | $186M / Series C / Nov 02, 2020 |
Co-Investors
Qiming Venture Partners
4 deals together
Lilly Asia Ventures
2 deals together
LYFE Capital
2 deals together
Morningside
2 deals together
Octagon Capital Advisors
2 deals together
3E Bioventures
1 deal together
About Loyal Valley Capital
Loyal Valley Capital is a thematic, research-driven private equity firm.
Loyal Valley Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jay Gu
Managing Director
|
|||
|
Roy Xie
Managing Director and Head of Healthcare Investments
|
|||
Andy Lin
Founding Partner
|
|||
Chengbin Li
Partner
|
|||
Jason Zhao
Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Roy Xie invest in?
Roy Xie invests primarily in Biotechnology, Life Science and Therapeutics startups, most often at Series B and Series A stage. Most of the 5 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Roy Xie last invest?
The most recent investment recorded for Roy Xie closed in Mar 2022. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
